Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
95.27
-3.83 (-3.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
↗
June 16, 2025
Curious about the S&P500 stocks that are showing activity before the opening bell on Monday?
Via
Chartmill
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses
↗
June 16, 2025
Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, supporting further development.
Via
Benzinga
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
↗
June 16, 2025
Via
Benzinga
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism
↗
June 16, 2025
Stifel also upgraded the stock to ‘Buy’ with a $107 price target.
Via
Stocktwits
Where Incyte Stands With Analysts
↗
June 03, 2025
Via
Benzinga
Earnings Scheduled For April 29, 2025
↗
April 29, 2025
Via
Benzinga
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
June 15, 2025
From
QIAGEN N.V.
Via
Business Wire
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
June 15, 2025
From
Incyte
Via
Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
June 12, 2025
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Incyte
Via
Business Wire
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
June 03, 2025
From
Incyte
Via
Business Wire
INCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech
↗
May 30, 2025
INCYTE CORP (NASDAQ:INCY) presents a compelling value case with strong profitability, low debt, and an attractive valuation. The biotech firm's fundamentals suggest potential upside for long-term...
Via
Chartmill
Incyte to Present at Upcoming Investor Conference
May 27, 2025
From
Incyte
Via
Business Wire
What's going on in today's session: S&P500 movers
↗
May 20, 2025
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
3 Mid-Cap Stocks with Questionable Fundamentals
May 20, 2025
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...
Via
StockStory
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
May 15, 2025
From
Incyte
Via
Business Wire
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
May 13, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit...
Via
StockStory
Topics
World Trade
These S&P500 stocks that are showing activity before the opening bell on Thursday.
↗
May 08, 2025
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?
Via
Chartmill
INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals.
↗
May 08, 2025
INCYTE CORP may be an undervalued stock option. NASDAQ:INCY retains a strong financial foundation and an attractive price tag.
Via
Chartmill
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2025
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
May 01, 2025
From
Incyte
Via
Business Wire
INCYTE CORP (NASDAQ:INCY) – A Look at Its Dividend Potential
↗
May 01, 2025
INCYTE CORP (NASDAQ:INCY) – A Look at Its Dividend Potential
Via
Chartmill
9 Analysts Have This To Say About Incyte
↗
April 30, 2025
Via
Benzinga
Discover the top S&P500 movers in Tuesday's after-hours session.
↗
April 29, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top S&P500 gainers and losers driving the post-market movements.
Via
Chartmill
Tuesday's pre-market session: top gainers and losers in the S&P500 index
↗
April 29, 2025
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via
Chartmill
3 Value Stocks Facing Headwinds
April 29, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...
Via
StockStory
Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?
↗
April 29, 2025
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and...
Via
Benzinga
Topics
Bonds
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers
April 29, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit...
Via
StockStory
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 29, 2025
From
Incyte
Via
Business Wire
Incyte (INCY) Q1 Earnings Report Preview: What To Look For
April 28, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
Government
World Trade
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
